Due to the fact that the above-mentioned trials were under-powered to assess the risk of thrombosis, it is still not known whether dual therapy (a NOAC plus a P2Y12 inhibitor) can sufficiently protect against myocardial infarction or stent thrombosis. The gene discussed is P2RY12; the disease is myocardial infarction.